Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 18, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - April 18, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/18/14 - ABPI welcomes the Medicines and Healthcare products Regulatory Agency (MHRA)'s priorities for 2014-15
In response Stephen Whitehead, Chief Executive of the Association of the British Pharmaceutical Industry, has said:. 'The MHRA are one of the best and most respected regulators in Europe and over the past year, they have played a key role in some very important developments that will positively impact both our industry and public health. 'The MHRA
4/18/14 - Actavis Confirms Favorable Ruling in Generic Lialda Patent Suit
By a News Reporter-Staff News Editor at Health& Medicine Week Actavis plc confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda infringes United States Patent No. 6,773,720. Actavis' Abbreviated New Drug Application for its generic version of Lia
4/18/14 - AmpliPhi to Present at 13th Annual Needham Healthcare Conference
By a News Reporter-Staff News Editor at Drug Week AmpliPhi BioSciences Corporation., the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that Philip Young, President and CEO, will be presenting a corporate overview at the 13th Annual Needham Healthcare Conference on Tue
4/18/14 - Armenia to take part in pharmaceutical exhibition held in EU [Armenpress News Agency]
This year, from October 7 to 9, the country will represent its capabilities in CPhi Worldwide in the capital of France Paris. "Armenpress" was informed about this from Samvel Zakaryan the Executive Director of the Medicine Producers and Importers Union of Armenia. "The opportunity of participation in such large-scale exhibitions was given t
4/18/14 - BioAlliance Pharma and Topotarget to Merge [Health & Beauty Close - Up]
BioAlliance Pharma SA, a company specialized in the development of drugs within orphan oncology diseases, and Topotarget A/S, a Scandinavian-based biopharmaceutical company, have announced their intention to merge to create a leading orphan oncology company with a highly complementary pipelines of late-stage products addressing significant unmet...
4/18/14 - BioPharm America 2014 to Returns to Boston's Copley Place [Health & Beauty Close - Up]
Produced by EBD Group in collaboration with the Massachusetts Biotechnology Council, the September 22-24 event will bring the global life science industry to Boston to facilitate strategic collaborations with leading companies. AstraZeneca, Bayer HealthCare, Bristol Myers Squibb, EMD Serono, Novo Nordisk, and Shire are just a few large drug develop
4/18/14 - Boston Scientific Receives FDA Approval of New Defibrillators and Heart Failure Devices [Professional Services Close - Up]
Boston Scientific Corp. has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. These newly approved devices continue the Boston Scientific history of projected longevity and a six-year CRT-D warranty. Extending the Boston Scientific portfolio of defibrillators, the ICDs in t
4/18/14 - Carestream's New Bone Suppression Software Receives FDA Clearance, Now Available Worldwide
By a News Reporter-Staff News Editor at Health& Medicine Week "Our new software collects radiation dose details from our CR and DR systems and sends this data to PACS systems that support the IHE dose monitoring profile," said Helen Titus, Carestream's Marketing Director of X-ray Solutions. "We are one of the first companies to provide radiation
4/18/14 - Cellceutix Study Shows Cellceutix Antibiotic Active Against Drug- Resistant Superbug Klebsiella Pneumoniae [Professional Services Close - Up]
Cellceutix Corp., a clinical stage biopharmaceutical company developing therapies in oncology, dermatology, and antibiotic applications, reports favorable results in a recently completed preclinical study evaluating its novel antibiotic compounds against specific strains of multi-drug resistant Klebsiella pneumoniae. According to a release, in a...
4/18/14 - Certara Purchases Specialty Contract Research Organization Synchrogenix [Health & Beauty Close - Up]
Certara, a technology-enabled drug development and drug safety consultancy, announced that it has acquired specialty contract research organization Synchrogenix Information Strategies Inc.. Donald A. Deieso, Chairman of Certara, said, "Pharmaceutical companies are looking for greater value and increased synergies from their outsourcing partners.
4/18/14 - Data on Clinical Pharmacy and Therapeutics Detailed by Researchers at University of Tokyo
By a News Reporter-Staff News Editor at Drug Week New research on Drugs and Therapies is the subject of a report. According to news reporting originating in Tokyo, Japan, by NewsRx journalists, research stated, "What is known and objective Decline in research and development productivity and changes in the business environment have led to pharmac
4/18/14 - Easton Pharmaceuticals Inks 'Viorra' Distribution Deal for Mexico [Professional Services Close - Up]
Easton Pharmaceuticals announced that BMV Medica, S.A. de C.V., a Mexican regulatory company and distributor of pharmaceutical products have signed an exclusive agreement to distribute Easton's "Viorra" product in Mexico. Carla Pepe, CEO of Easton Pharmaceuticals, stated, "BMV Medica, as previously announced, is the company's current regulatory con
4/18/14 - FDA approves Ragwitek for short ragweed pollen allergies
Release date- 17042014- The U.S. Food and Drug Administration today approved Ragwitek, the first allergen extract administered under the tongue to treat short ragweed pollen induced allergic rhinitis, with or without conjunctivitis, in adults 18 years through 65 years of age. 'The approval of Ragwitek offers millions of adults living with ragweed p
4/18/14 - FDB to Present Drug Pricing Analysis Poster Comparing AWP and WAC to AAC Benchmarks
By a News Reporter-Staff News Editor at Insurance Weekly News FDB, the leading provider of clinical drug knowledge that helps improve medication-related decisions and patient outcomes, announced that it will present a poster at the Academy of Managed Care Pharmacy 26th Annual Meeting, April 1- 4, 2014, in Tampa, Florida and the International Soci
4/18/14 - Galectin Announces First Patient Dosed in Phase 1 Trial of GR-MD-02; Targeted Medical Pharma Completes Middle East Distribution Agreement
Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. "These positive results have propelled the enrollment of the second cohort with strong participation across our clinical trial sites. In 2013, Galectin Therapeutics received Fast Track designation from the FDA for this clinical development..
4/18/14 - GlaxoSmithKline Assigned Patent for Tetrahydroquinoline Derivatives and Their Pharmaceutical Use
ALEXANDRIA, Va., April 18 GlaxoSmithKline, Philadelphia, has been assigned a patent developed by seven co-inventors for "tetrahydroquinoline derivatives and their pharmaceutical use." The co-inventors are Emmanuel Hubert Demont, Stevenage, United Kingdom, Neil Stuart Garton, Stevenage, United Kingdom, Romain Luc Marie Gosmini, Les Ulis, France, T
4/18/14 - GSK and Genmab receive FDA approval for Arzerra (ofatumumab) as first-line treatment in combination with chlorambucil for patients with Chronic Lymphocytic Leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate
Release date- 17042014- GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration has approved a Supplemental Biologic License Application for the use of Arzerra, a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic...
4/18/14 - Ireland : NIBRT hosts biopharma job fair advertising 750 open positions [TendersInfo (India)]
The National Institute for Bioprocessing Research and Training NIBRT today Wednesday held its inaugural Careers in Biopharma job fair with 15 companies, recruiting for over 750 open positions, from across the biopharma sector taking part. Dr Reg Shaw, CEO of NIBRT said, The Irish biopharma industry continues to go from strength-to-strength includin
4/18/14 - Japan : "ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed... [TendersInfo (India)]
Takeda Pharmaceutical Company Limited announced today that "ADCETRIS 50 mg for intravenous drip infusion" is now available for the treatment for patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma in Japan. ADCETRIS received orphan drug designation from the Ministry of Health,
4/18/14 - Lannett Gets FDA Approval for Diazepam Oral Solution (Concentrate), 5 mg/mL [Health & Beauty Close - Up]
Lannett Company, Inc. said that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Diazepam Oral Solution, 5 mg/ mL, a Schedule C-IV controlled drug. "We believe our ANDA for Diazepam Oral Solution, 5 mg/mL was the first bioequivalent Diazepam Oral Solution product approved by the FDA,"
4/18/14 - Luoxis Obtains CE Marking for RedoxSYS? Diagnostic System
By a News Reporter-Staff News Editor at Health& Medicine Week Ampio Pharmaceuticals, Inc., announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained CE Marking in Europe for its RedoxSYS? Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body. This regulatory clear
4/18/14 - OMICS Group BABE-2014 Summit to Revolutionize the Next Generation Medicines
Organizing Committee Members Include: Wolfgang Sadee, The Ohio State University, USA; Diane J Burgess, University of Connecticut, USA; Lakshmi Putcha, NASA, USA; Sean Zhang, Sino-American Pharmaceutical Professionals Association, USA; Mirko Diksic, McGill University, Canada; Mohammad Khalid Parvez, King Saud University, Saudi Arabia;. OMICS Group o
4/18/14 - PanOptica Secures $45 Million to Finance Clinical Development of Anti-VEGF Eye Drop for Wet AMD [Health & Beauty Close - Up]
PanOptica, Inc., a private biopharmaceutical company focusing on licensing and developing ophthalmology therapies, announced that it has raised up to $45 million in a Series B financing to fund the clinical program for its lead compound, PAN-90806, a pharmacologically small-molecule selective inhibitor of VEGF signaling being investigated as a topi
4/18/14 - Patent Issued for Pharmaceutical Formulations of Modafinil
By a News Reporter-Staff News Editor at Health& Medicine Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Heacock, Craig S.; Parikh, Alpa B.; Patel, Piyush R., filed on August 21, 2012, was published online on April 1, 2014. The patent's assignee for patent number 8686047 is Cephalon, Inc.. No. 4,177,290, a
4/18/14 - Patent Issued for Use of Amisulpride as an Anti-Emetic
By a News Reporter-Staff News Editor at Drug Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Gilbert, Julian Clive; Gristwood, Robert William; Cooper, Nicola; Fox, Gabriel, filed on July 26, 2012, was published online on April 1, 2014. The patent's assignee for patent number 8686019 is Acacia Pharma Limite
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool
An Overview of Complementary and Alternative Medicine
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415